Rheumatology
Ehlers-Danlos / Hypermobility Spectrum
Beighton score, distinguish hypermobility spectrum from hEDS / classical / vascular EDS, multidisciplinary management.
Source: International EDS Consortium 2017
Step 1 of ~3
info
Beighton Score + Pattern
Beighton score (0–9): each side — passive 5th finger dorsiflexion >90° (1), passive thumb to forearm (1), elbow hyperextension >10° (1), knee hyperextension >10° (1), forward flexion to floor (1). Beighton ≥4 (or ≥5 prepubertal, ≥1 in age >50) = generalised hypermobility.
Distinguishing features for EDS subtypes:
• Classical EDS (cEDS): skin hyperextensibility + atrophic scarring + Beighton ≥5.
• Vascular EDS (vEDS): thin translucent skin + arterial / intestinal / uterine rupture + family history.
• Hypermobile EDS (hEDS): generalised hypermobility + systemic features + family history (no specific gene yet).
• Hypermobility spectrum disorder (HSD): hypermobility + symptoms but criteria for hEDS not met.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Piperacillin/Tazobactam · Extended-spectrum beta-lactam + beta-lactamase inhibitor
- Posaconazole · Extended-Spectrum Triazole — Aspergillus / Mucor / Prophylaxis in Immunocompromised
- Chloramphenicol · Antibiotic — broad-spectrum
- Fidaxomicin · Macrocyclic antibiotic (narrow-spectrum)
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only. Always apply local guidelines and clinical judgement.